Library Item - Page 41 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Evaluating the outcomes of current therapies after surgery for patients with stage III melanoma who did not undergo complete lymph node dissection.

Evaluating the outcomes of current therapies after surgery for patients with stage III melanoma who did not undergo complete lymph node dissection.

Posted by on Oct 31, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the outcomes of immune and molecular targeted therapies after surgery for patients with stage III melanoma who did not undergo complete lymph node dissection. The data showed that the immune and targeted therapies after surgery were associated with increased survival without metastasis among these patients. Some...

Read More

Evaluating the clinical outcomes in patients with relapsed or refractory classical Hodgkin lymphoma after first-line treatment.

Evaluating the clinical outcomes in patients with relapsed or refractory classical Hodgkin lymphoma after first-line treatment.

Posted by on Oct 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the characteristics, treatment patterns, and outcomes of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (HL) after treatment with first-line therapy.  Some background HL is a cancer of white blood cells. Most patients with HL respond to first-line chemotherapy regimens. However, up to...

Read More

Evaluating the effectiveness and safety outcomes of second radiation therapy in patients with locally recurrent prostate cancer.

Evaluating the effectiveness and safety outcomes of second radiation therapy in patients with locally recurrent prostate cancer.

Posted by on Oct 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of re-irradiation for the treatment of patients with locally recurrent prostate cancer. The data showed that the use of re-irradiation in these patients was associated with good outcomes and low toxicity. Some background Radiotherapy (RT) is an effective treatment for localized...

Read More

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

Posted by on Oct 31, 2021 in Melanoma | 0 comments

In a nutshell This study investigated the optimal doses of hypofractionated stereotactic radiation therapy (HSRT) for patients with brain metastases (BM). The data showed that a HSRT dose of 30 Gy or higher delivered in 5 daily fractions was safe and effective in these patients. Some background Stereotactic radiosurgery (SRS) is commonly...

Read More

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

Posted by on Oct 31, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the optimal doses of hypofractionated stereotactic radiation therapy (HSRT) for patients with brain metastases (BM). The data showed that a HSRT dose of 30 Gy or higher delivered in 5 daily fractions was safe and effective in these patients. Some background Stereotactic radiosurgery (SRS) is commonly used in...

Read More

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

Evaluating treatment outcomes of hypofractionated stereotactic radiotherapy in patients with brain metastases.

Posted by on Oct 31, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the optimal doses of hypofractionated stereotactic radiation therapy (HSRT) for patients with brain metastases (BM). The data showed that a HSRT dose of 30 Gy or higher delivered in 5 daily fractions was safe and effective in these patients. Some background Stereotactic radiosurgery (SRS) is commonly used in...

Read More

Evaluating the effectiveness of extended robot-assisted prostate surgery and extended pelvic lymph node dissection in patients with very high-risk prostate cancer.

Evaluating the effectiveness of extended robot-assisted prostate surgery and extended pelvic lymph node dissection in patients with very high-risk prostate cancer.

Posted by on Oct 31, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed the effectiveness of extended robotic-assisted laparoscopic prostatectomy (eRALP) with extended pelvic lymph node dissection (ePLND) without any other additional treatments for patients with very-high-risk localized prostate cancer (PCa). The study found that eRALP with ePLND alone was safe and effective...

Read More

Evaluating the effectiveness of EGFR-TKIs first-line treatment and performance status in older patients with EGFR-mutant NSCLC.

Evaluating the effectiveness of EGFR-TKIs first-line treatment and performance status in older patients with EGFR-mutant NSCLC.

Posted by on Oct 31, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) first-line treatment and performance status in older patients with EGFR-mutant non-small-cell lung cancer (NSCLC). The data showed that older patients with EGFR-mutated NSCLC who received EGFR-TKI first-line treatment with a...

Read More

Which type of CAR T cell therapy is best for patients with relapsed or refractory large B cell lymphoma?

Which type of CAR T cell therapy is best for patients with relapsed or refractory large B cell lymphoma?

Posted by on Oct 26, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors compared the safety and effectiveness of lisocabtagene maraleucel (liso-cel; Breyanzi) and axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed or refractory (r/r) large B cell lymphoma (LBCL). The study found that both treatments were similarly effective but liso-cel was better tolerated in these...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor